PFM
PSTX

Privium Fund Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Privium Fund Management’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-77,500
Closed -$222K – 89
2024
Q3 		$222K Buy
+77,500
New +$240K 0.06% 74

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Privium Fund Management's PSTX Position: Q4 2024 in Review

Privium Fund Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2024, closing a stake of 77,500 shares — an estimated $222K sold.

Privium Fund Management first reported a position in PSTX in Q3 2024 and held it in 1 quarter. The position peaked at $222K in Q3 2024. 115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.

  • Privium Fund Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Privium Fund Management sold 77,500 Poseida Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $222K.
  • Privium Fund Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2024 and held it in 1 quarter.
  • Privium Fund Management's Poseida Therapeutics, Inc. Common Stock position peaked at $222K in Q3 2024.
  • 115 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Privium Fund Management's 13F filing for Q4 2024, filed 11 Feb 2025.